Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Treatment options for patients with advanced head and neck squamous cell carcinoma (HNSCC) are scarce. This phase 2 study was conducted to evaluate the safety, tolerability, pharmacokinetics, and efficacy of dasatinib in this setting. METHODS: Patients with recurrent and/or metastatic HNSCC after platinum‐based therapy were treated with dasatinib either orally or via percutaneous feeding gastrostomy (PFG). Primary endpoints were 12‐week progression‐free survival (PFS) and objective response rate with a 2‐stage design and early withdrawal if the 12‐week PFS rate was ≤20% and no patients had an objective response (OR). Forty‐nine serum cytokines and angiogenic factors (CAFs) were analyzed from treated patients. RESULTS: Of the 15 patients enrolled, 12 were evaluable for response, and all patients were evaluable for toxicity. No OR was observed and 2 patients (16.7%) had stable disease (SD) at 8 weeks. The median treatment duration was 59 days, the median time to disease progression was 3.9 weeks, and the median survival was 26 weeks. One patient required a dose reduction, 3 patients required dose interruptions, and 4 patients were hospitalized for toxicity. Dasatinib inhibited c‐Src both when administered orally and via PFG. Greater mean drug exposure, decreased half‐life, and greater maximum concentration were observed in patients receiving dasatinib via PFG. Eleven baseline CAFs were associated with treatment outcome and 1 CAF, macrophage migration inhibitory factor, was found to be differentially modulated in correlation with SD versus disease progression. CONCLUSIONS: Single‐agent dasatinib failed to demonstrate significant activity in patients with advanced HNSCC, despite c‐Src inhibition. The toxicity profile was consistent with that reported in other solid tumors, and the drug can be given via PFG tube. Cancer 2011. © 2010 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Soulieres, D., Senzer, N. N., Vokes, E. E., Hidalgo, M., Agarwala, S. S., & Siu, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.075 · Cited by 807
Demetri, G. D., Lo Russo, P., MacPherson, I. R. J., Wang, D., Morgan, J. A., Brunton, V. G., Paliwal, P., Agrawal, S., Voi, M., & Evans, T. R. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0224 · Cited by 150
Cited by
Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients
Yuan, Y., Liu, L., Chen, H., Wang, Y., Xu, Y., Mao, H., Li, J., Mills, G. B., Shu, Y., Li, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.001 · Cited by 331
Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far
Martellucci, S., Clementi, L., Sabetta, S., Mattei, V., Botta, L., & Angelucci, A. (2020) · Cancers · doi:10.3390/cancers12061448 · Cited by 139
“II none SD = 17% 100 mg twice daily reduced to 150 mg daily or 50 mg twice daily 2011 [153]”
Src family kinases and paclitaxel sensitivity
Le, X.-F., & Bast, Jr. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.4.16430 · Cited by 79
Sharma, M. R., Wroblewski, K., Polite, B. N., Knost, J. A., Wallace, J. A., Modi, S., Sleckman, B. G., Taber, D., Vokes, E. E., Stadler, W. M., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9681-x · Cited by 49
Metadata
- Authors
- Brooks, H. D., Glisson, B. S., Bekele, B. N., Ginsberg, L. E., El‐Naggar, A., Culotta, K. S., Takebe, N., Wright, J., Tran, H. T., & Papadimitrakopoulou, V. A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2010-11-29
- Volume
- 117
- Issue
- 10
- Pages
- 2112-2119
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2138501030
- Cited by
- 116
- References
- 2
- FWCI
- 8.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. https://app.cochat.ai/papers/10.1002/cncr.25769
- The paper
- Brooks, H. D., Glisson, B. S., Bekele, B. N., Ginsberg, L. E., El‐Naggar, A., Culotta, K. S., Takebe, N., Wright, J., Tran, H. T., & Papadimitrakopoulou, V. A. (2011). Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer. https://doi.org/10.1002/cncr.25769
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.